TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05017792

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Astrazenica vaccine
Description: COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Astrazenica vaccine
Description: COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Astrazenica vaccine
Description: COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Astrazenica vaccine
Description: COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Astrazenica vaccine
Description: COVID-19 vaccines should be administered by intramuscular (IM) injection, preferably into the deltoid muscle of the upper arm. Individuals who have minimal muscle mass in the deltoid area of the upper arm, or a particular reason to avoid immunization in the deltoid muscle, can be given their vaccine in the vastuslateralis muscle in the thigh if necessary.
Study: NCT06573346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical spinal stabilization exercise
Description: The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
Study: NCT06296940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Description: Written Exposure Therapy is a brief, evidenced based intervention for PTSD. WET is generally delivered individually across 5 sessions in which the therapist guides the patient through writing exercises. Across exposure sessions, participants experience habituation so that their symptoms decrease by the end of treatment. WET has an established evidence base in general outpatient psychotherapy for PTSD, but has not been adapted or tested in residential SUD treatment settings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on their substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual will include a variety of standard care services offered in short term residential treatment. For example, participants receiving TAU will participate in individual case management/general counseling sessions focused on their substance use disorder and its consequences, group based psychoeducation sessions, group based counseling sessions (e.g., relapse prevention planning), individual services with a medical provider and pharmacotherapy (e.g., for withdrawal, relapse prevention, or co-occurring conditions)
Study: NCT05370781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Led Diabetes Self-Management Support
Description: While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Self-Management Education
Description: Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education
Description: Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom platform.
Study: NCT06081010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Intervention
Description: Trained CHWs will hold group meetings or home visits using a locally adapted manual for HTN management. CHWs will visit homes in their areas and measure BP. High BP clients will be taken to the nearest health center. CHWs will enroll individuals with preHTN and HTN and conduct 4 follow-up group meetings or home visits with them every 3 months. Participants will be invited to attend CHW lead group-based counseling. For those with uncontrolled HTN who have difficulty adhering to prescribed HTN management and not willing or able to attend group meetings, CHWs will conduct follow-up home visits. First meeting (about 90 minutes), CHWs will explain purpose of the meeting and discuss HTN and its consequences. CHWs will apply techniques to initiate dialogue and reflection regarding lifestyle modifications and choose goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent meetings (about 60 minutes), the CHWs will measure BP and address ongoing problems.
Study: NCT06092827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non weight-bearing physical activity program
Description: 12-week duration, 2 supervised trainings/week, 1 unsupervised home-based training/week Aerobic, resistance and flexibility exercises
Study: NCT06584617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Berovenal®
Description: Easy to spread, water-washable, light brown, turbid hydrogel in tube containing 30 g of hydrogel and closed with a plastic screw cap.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NU-GEL Hydrogel with Alginate
Description: Transparent, easy to spread and water-washable hydrogel in ampoule (concertina pack) containing 25 g or 15 g of hydrogel and closed with a plastic cap.
Study: NCT05105360

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure method of Petersen's space
Description: Surgeons closed Petersen's space between the mesentery of the jejunal Roux limb and the mesentery of the transverse colon at the posterior side of esophago-jejunostomy or gastro-jejunostomy from the mesentery root to the bowel side using a nonabsorbable barbed suture V-LocTM 3-0 (Medtronic VR, Minneapolis, MN, USA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesentery fixation method
Description: Surgeons fixed the jejunal mesentery (jejunojejunostomy\[J-J\] distal 30 cm) to the transverse mesocolon using non-absorbable barbed suture VLocTM 3-0 sutures. The suture area was exposed by grasping the jejunum side mesentery (jejunal side, at site 30cm distal J-J) and the transverse mesocolon (colonic side). The jejunal side mesentery was fixed to the colonic side mesocolon between the jejunum and the transverse colon using nonabsorbable barbed V-LocTM 3-0 sutures.The suture started between jejunal mesentery just below of SMA vascular arcade and transverse mesocolon, and it finished when it reaches the root of the mesentery. To anchor the mesentery, continuous suturing with V-Loc two-point backward sutures were performed at the final step.
Study: NCT05881941

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: using a soundproof nebulizer with a music and a funny mask added
Description: There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: using a silent nebulizer with no extra attachments
Description: There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: using a routinely employed nebulizer
Description: There were 3 groups in the study. These were Experimental Group 1, using a soundproof nebulizer with a music and a funny mask added, Experimental Group 2 using a silent nebulizer with no extra attachments, and a Control Group using a routinely employed nebulizer
Study: NCT05357209

Intervention type: DEVICE
Group type: OTHER
Intervention: Avidhrt Sense Heart Monitor
Description: Use of Avidhrt Sense Heart Monitor review ECG signals.

Intervention type: DEVICE
Group type: OTHER
Intervention: Avidhrt Sense Heart Monitor
Description: Use of Avidhrt Sense Heart Monitor review ECG signals.
Study: NCT05351281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDSS-OPTIMED
Description: The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient with a life expectancy of less than 3 months.
Study: NCT06015217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetaphil Healing Ointment
Description: Subjects will use Cetaphil Healing Ointment on the diaper rash area with every diaper change
Study: NCT03448601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally tailored brochure intervention group
Description: Culturally-tailored Alzheimer's Disease and precision medicine educational brochure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally tailored video intervention group
Description: Culturally-tailored Alzheimer's Disease and precision medicine educational video.
Study: NCT05547932

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIB+SAP blocks
Description: RIB block will be performed after endotracheal intubation, then a SAP block will be performed. No other intervention will be performed to the patients.
Study: NCT05874934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrahepatic biliary stent with retrieval string
Description: Plastic biliary stent with 3-0 nylon (ethilon) thread tied to the distal end of the stent through the existing sidehole.
Study: NCT03890341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinylestradiol
Description: A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg will be administered orally on Days 1, 13 and 19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64530440
Description: A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
Study: NCT05955638

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiSight contact lenses
Description: Contact lens for myopia management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proclear contact lenses
Description: Single vision contact lens as control
Study: NCT05140278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argesun 60mg (1 step parenteral artesunate)
Description: Each vial of powder contains 60mg artesunate. Each ampoule of 6 ml solvent contains: sodium bicarbonate 8.4mg/ml; arginine 20mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesun 60mg (2-step parenteral artesunate)
Description: Each vial of powder contains 60 mg artesunate. Each ampoule of 1 ml solvent contains 50 mg sodium bicarbonate. Each ampoule of 5 ml diluent contains 45 mg sodium chloride.
Study: NCT06057896

Intervention type: DIETARY_SUPPLEMENT
Intervention: inositol, phytoestrogens, cocoa polyphenols
Description: myo-inositol, soy isoflavones and cocoa polyphenols
Study: NCT05446740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 1
Description: Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 1
Description: Dose level 1 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 1 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
Study: NCT05854173

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pendulum Exercises
Description: Compare The Effect of Pendulum Exercises Among the Patients of Adhesive Capsulitis
Study: NCT05446740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK4382276A Dose level 2
Description: Dose level 2 of GSK4382276A is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA GSK4382276A Dose level 2 and OA GSK4382276A Selected Dose level from YA groups, at Day 1. Potential intermediate dose levels may be evaluated, with the total number of dose levels per age group not exceeding 5.
Study: NCT05854173

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kaltenborn Mobilization
Description: Compare The Effect of Kaltenborn Mobilization Among the Patients of Adhesive Capsulitis
Study: NCT04871724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-938
Description: Subjects will receive EDP-938 once daily on Days 1 and 14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Subjects will receive fluconazole once daily on Days 5 to 18
Study: NCT06422156

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation
Description: Patients will receive SBRT with doses ranging from 35-40 Gy in five fractions.
Study: NCT05446740

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FDQ21A-NH
Description: Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FDQ21A-NH
Description: Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 1 and OA Control groups, at Day 1.
Study: NCT06422156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg on day 1 and 8 of a 21-day cycle until disease progression.
Study: NCT05446740

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FDQ22A-NH
Description: Single dose of FDQ21A-NH is administered intramuscularly in the upper deltoid region of the non-dominant arm to participants in YA Control 2, at Day 1.
Study: NCT06422156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mono-chemotherapy
Description: Patients will receive mono-chemotherapy (Gemcitabine, S-1 or capecitabine) until disease progression.
Study: NCT06574503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 40mg
Description: 2X20mg tablets taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GP681 Simulant
Description: Placebo tablets matching GP681 40mg
Study: NCT04582864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flotetuzumab
Description: Will be provided by MacroGenics Inc.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusion
Description: DLI represents a non-specific form of adoptive cell therapy which involves infusion of a pool of allogeneic immune cells, including CD4+ T cells, CD8+ T cells, regulatory T cells (T Regs), natural killer (NK) cells and professional antigen presenting cells.
Study: NCT05743478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forging Hopeful Futures
Description: Forging Hopeful Futures is a 12 session curriculum for youth ages 13-19 that uses strengths-based and healing-centered approaches to critically examine structural forces that perpetuate racial and gender injustice, develop leadership skills in promoting gender equitable relationship norms, non-violent practices, and upstander skills, and enhance economic justice through job skills and employment opportunities. Through 12 sessions (3 hours/session) over a 6 to 12 week period, Forging Hopeful Futures combines racial, gender, and economic justice content with leadership development and workforce development opportunities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Check-ins
Description: Individual wellness checks will occur through a strengths-based telephone conversation focused on wellness resources. Youth will be provided with tailored resources based on needs identified during the call. Youth will be offered the option for additional phone check-ins to coordinate access to community resources and connection to individualized behavioral health supports if desired.
Study: NCT06543004

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: AH plus sealer
Description: Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bioceramic sealer
Description: Root canal sealer will be placed inside the root canals during obturation procedure to seal dentine wall and reinforce the remaining tooth tissue.It will be selected randomly to the study samples.
Study: NCT05151822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training session with the virtual reality mask
Description: Patients will have a training session with the virtual reality mask, the day before surgery. The training consists in the realization, by the patient, of a series of language or neuropsychological tests and evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated)).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring of the device
Description: In the operating room : installation and per-operative monitoring of the device. If the device was removed, the list of device side effects or surgery-related adverse events that was required discontinuation of the device will be established.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptability of the device
Description: After the surgery: evaluation of the acceptability of the device by the patient with Visual Analog Scale (device tolerance from 0 (intolerable) to 10 (completely tolerated))

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient state of anxiety
Description: Assessing patient's state of anxiety with the State-Trait Anxiety Inventory (STAI) after surgery.
Study: NCT04698278

Intervention type: DEVICE
Intervention: PanOptix Trifocal Intraocular Lens
Description: This is a FDA approved trifocal lens that will be placed in patients who have had previous myopic LASIK or PRK.
Study: NCT05478603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: PF-07081532 20 milligrams (mg), 1 tablet orally, once on Day 1
Study: NCT05408533

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-Way Foley Urethral Urinary Catheter
Description: Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 2-Way Foley Urethral Urinary Catheter
Description: Comparing two types of catheter (silver-coated silicone versus silicone) after Pelvic Reconstructive Surgery (PRS) to compare Urinary Tract Infection (UTI) rates
Study: NCT04274517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sterile Water
Description: 1L of sterile water used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3.5% Betadine
Description: 1L of 3.5% betadine used in surgical splash basins during total joint arthroplasty to clean surgical instrumentation.
Study: NCT06385145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with new preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with new preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation (R)
Description: A single subcutaneous injection of PEG-rhGH with present preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation (R)
Description: A single subcutaneous injection of PEG-rhGH with present preparation